Faculty Collaboration Database

Medical College of Wisconsin

CTSI Research Informatics REDCap

James P. Thomas PhD, MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Member of the Cancer Center
Member of the Center for Disease Prevention Research (CDPR)

Send Message

Request Meeting

View Curriculum Vitae

Publications (75)

Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. (Kamgar M, Hobbs GA, Davidson R, Dorbin D, Herrera J, Langenheim JF, Burge RA, Aldakkak M, Conrardy RD, Szabo A, Thalji SZ, Mayer B, Grahl JJ, Chung BY, Phan A, Thomas JP, Seo YD, Evans DB, Christians KK, Erickson B, Hall W, George B, Tsai S, Lytle NK, Der CJ, Kurzrock R, McFall T) Cancer Res 2025 Oct 24 PMID: 41134578 10/24/2025

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. (Mehdi M, Szabo A, Shreenivas A, Thomas JP, Tsai S, Christians KK, Evans DB, Clarke CN, Hall WA, Erickson B, Ahmed G, Thapa B, McFall T, George B, Kurzrock R, Kamgar M) Ther Adv Med Oncol 2024;16:17588359241253113 PMID: 38770091 PMCID: PMC11104030 SCOPUS ID: 2-s2.0-85193752803 05/21/2024 4 Citations

p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. (Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons Bach R, Fu L, Chen G) Cancer Res 2020 Aug 15;80(16):3251-3264 PMID: 32580961 PMCID: PMC9358694 SCOPUS ID: 2-s2.0-85089787021 06/26/2020 68 Citations

Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. (Stein A, Strong E, Clark Gamblin T, Clarke C, Tsai S, Thomas J, George B, Mogal H) Ann Surg Oncol 2020 Jan;27(1):85-97 PMID: 31583543 SCOPUS ID: 2-s2.0-85074461946 10/05/2019 31 Citations

5-FU/leucovorin, uifinotecan, oxaliplatin (FOLFIRINOX)induction followed by chemoXRT in borderline resectable pancreatic cancer. (Jordan Kharofa, Tracy R. Kelly, Paul S. Ritch, Ben George, Lauren Allison Wiebe, James P. Thomas, Kathleen K. Christians, Douglas B. Evans, Beth Erickson ) Journal of Clinical Oncology 10.1200/jco.2012.30.15_suppl.e1461 Journal of Clinical Oncology 30, no. 15_suppl -published online before print 01/09/2018

A Comprehensive Program for the Enhancement of Accrual to Clinical Trials. (Porter M, Ramaswamy B, Beisler K, Neki P, Single N, Thomas J, Hofacker J, Caligiuri M, Carson WE 3rd) Ann Surg Oncol 2016 Jul;23(7):2146-52 PMID: 26790668 SCOPUS ID: 2-s2.0-84954569217 01/23/2016 9 Citations

Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. (Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK) PLoS One 2015;10(10):e0139940 PMID: 26448327 PMCID: PMC4598149 SCOPUS ID: 2-s2.0-84948706797 10/09/2015 47 Citations

PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue (Thomas JP, Geiger PG) Cancer Res Thomas JP, Geiger PG. Abstract 4443: PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue. Cancer Res. August 1, 2015 75; 4443. 08/01/2015

p38γ MAPK is required for inflammation-associated colon tumorigenesis. (Yin N, Qi X, Tsai S, Lu Y, Basir Z, Oshima K, Thomas JP, Myers CR, Stoner G, Chen G) Oncogene 2016 Feb 25;35(8):1039-48 PMID: 25961922 SCOPUS ID: 2-s2.0-84959509513 05/12/2015 37 Citations

Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. (Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC) Cancer Biol Ther 2015;16(5):764-9 PMID: 25778705 PMCID: PMC4622996 SCOPUS ID: 2-s2.0-84943767513 03/18/2015 20 Citations

Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. (Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T) Ann Surg Oncol 2015 Oct;22(11):3716-23 PMID: 25777092 SCOPUS ID: 2-s2.0-84941418828 03/18/2015 94 Citations

Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK) HPB (Oxford) 2015 Feb;17(2):131-9 PMID: 25123702 PMCID: PMC4299387 SCOPUS ID: 2-s2.0-84920841239 08/16/2014 21 Citations

Molecular profiling in gastric cancer: examining potential targets for chemotherapy. (Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC) J Surg Oncol 2014 Sep;110(3):302-6 PMID: 24844210 SCOPUS ID: 2-s2.0-84905367494 05/23/2014 9 Citations

Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. (Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK) Eur J Cancer 2014 Jul;50(10):1747-1757 PMID: 24767470 SCOPUS ID: 2-s2.0-84901752316 04/29/2014 79 Citations

Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, Turaga KK) Surg Endosc 2014 May;28(5):1505-14 PMID: 24687416 SCOPUS ID: 2-s2.0-84900328041 04/02/2014 8 Citations

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 PMID: 24569947 PMCID: PMC3958454 SCOPUS ID: 2-s2.0-84896486447 02/27/2014 178 Citations

Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. (Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, Thomas JP, Wong YL, Findling JW) Case Rep Endocrinol 2013;2013:675298 PMID: 24455332 PMCID: PMC3881387 01/24/2014

Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK) Ann Surg Oncol 2014 Jan;21(1):240-7 PMID: 24114054 SCOPUS ID: 2-s2.0-84891708354 10/12/2013 20 Citations

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. (Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE) Exp Ther Med 2011 Jan;2(1):119-123 PMID: 21373381 PMCID: PMC3046871 SCOPUS ID: 2-s2.0-78751615964 03/05/2011 8 Citations

A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. (Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL) Clin Colorectal Cancer 2010 Jul;9(3):157-61 PMID: 20643620 PMCID: PMC3058720 SCOPUS ID: 2-s2.0-77954913713 07/21/2010 8 Citations

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. (Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD) Cancer Chemother Pharmacol 2010 Oct;66(5):973-80 PMID: 20127092 PMCID: PMC2921466 SCOPUS ID: 2-s2.0-77956225836 02/04/2010 18 Citations

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. (Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH) Invest New Drugs 2011 Apr;29(2):316-22 PMID: 19997959 PMCID: PMC3038176 SCOPUS ID: 2-s2.0-79957532438 12/10/2009 5 Citations

NCCN Clinical Practice Guidelines in Oncology: colon cancer. (Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, National Comprehensive Cancer Network) J Natl Compr Canc Netw 2009 Sep;7(8):778-831 PMID: 19755046 SCOPUS ID: 2-s2.0-70349859891 09/17/2009 337 Citations

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. (Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA) Cancer J 2009;15(4):339-43 PMID: 19672152 SCOPUS ID: 2-s2.0-69549120297 08/13/2009 46 Citations

A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. (Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M) Cancer Chemother Pharmacol 2010 Apr;65(5):863-9 PMID: 19657639 PMCID: PMC4261191 SCOPUS ID: 2-s2.0-77649185248 08/07/2009

Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. (Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS) Oncology 2009;76(5):333-7 PMID: 19307739 SCOPUS ID: 2-s2.0-62649111529 03/25/2009 21 Citations

A phase I study of an oral simulated FOLFOX with high dose capecitabine. (Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G) Invest New Drugs 2009 Oct;27(5):461-8 PMID: 19129971 PMCID: PMC2899673 SCOPUS ID: 2-s2.0-70349235532 01/09/2009 7 Citations

Association of family history with cancer recurrence and survival among patients with stage III colon cancer. (Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS) JAMA 2008 Jun 04;299(21):2515-23 PMID: 18523220 PMCID: PMC3616330 SCOPUS ID: 2-s2.0-44649122161 06/05/2008 74 Citations

Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. (Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S) Clin Adv Hematol Oncol 2008 Jan;6(1):44-54 PMID: 18322441 SCOPUS ID: 2-s2.0-41449102603 03/07/2008 5 Citations

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. (LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J) Cancer Chemother Pharmacol 2008 Dec;63(1):109-15 PMID: 18322686 SCOPUS ID: 2-s2.0-53149091626 03/07/2008 18 Citations

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. (Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G) Cancer Chemother Pharmacol 2008 Sep;62(4):727-33 PMID: 18172649 SCOPUS ID: 2-s2.0-47549111409 01/04/2008 10 Citations

Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. (Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE) J Inorg Biochem 2008 Apr;102(4):693-8 PMID: 18061679 PMCID: PMC2390869 SCOPUS ID: 2-s2.0-40649118985 12/07/2007 28 Citations

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. (Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ) J Clin Oncol 2007 Aug 10;25(23):3456-61 PMID: 17687149 SCOPUS ID: 2-s2.0-34548160680 08/10/2007 417 Citations

Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. (Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G) Clin Cancer Res 2007 Jun 15;13(12):3623-9 PMID: 17510207 SCOPUS ID: 2-s2.0-34250755529 05/19/2007 14 Citations

Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. (Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D) Int J Radiat Oncol Biol Phys 2007 May 01;68(1):13-23 PMID: 17448867 SCOPUS ID: 2-s2.0-34247095550 04/24/2007 598 Citations

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. (McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G) Clin Cancer Res 2005 Nov 01;11(21):7851-60 PMID: 16278408 SCOPUS ID: 2-s2.0-27744563296 11/10/2005 144 Citations

A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. (Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP) Oncology 2005;69(2):130-4 PMID: 16118509 SCOPUS ID: 2-s2.0-25444506891 08/25/2005 16 Citations

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. (Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA) Clin Cancer Res 2005 May 01;11(9):3410-6 PMID: 15867242 SCOPUS ID: 2-s2.0-20944450476 05/04/2005 66 Citations

Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. (Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd) Oncology 2004;66(4):303-9 PMID: 15218298 SCOPUS ID: 2-s2.0-3042645045 06/26/2004 34 Citations

Gemcitabine, Paclitaxel, and piritrexim: a phase I study. (Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP) Am J Clin Oncol 2003 Jun;26(3):280-4 PMID: 12796601 SCOPUS ID: 2-s2.0-0037841388 06/11/2003 5 Citations

Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. (Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP) Int J Gastrointest Cancer 2002;32(2-3):125-8 PMID: 12794248 SCOPUS ID: 2-s2.0-0038308362 06/10/2003 67 Citations

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. (Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G) J Clin Oncol 2003 Jan 15;21(2):223-31 PMID: 12525513 SCOPUS ID: 2-s2.0-0037440123 01/15/2003 230 Citations

Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. (Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G) Invest New Drugs 2002 Nov;20(4):377-82 PMID: 12448654 SCOPUS ID: 2-s2.0-0036829343 11/27/2002 1 Citation

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. (Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G) Cancer Chemother Pharmacol 2002 Dec;50(6):465-72 PMID: 12451473 SCOPUS ID: 2-s2.0-0036450831 11/27/2002 121 Citations

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. (Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd) J Clin Oncol 2002 Aug 01;20(15):3270-5 PMID: 12149301 SCOPUS ID: 2-s2.0-0036682041 08/01/2002 730 Citations

Phase I clinical and pharmacokinetic trial of irofulven. (Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H) Cancer Chemother Pharmacol 2001 Dec;48(6):467-72 PMID: 11800027 SCOPUS ID: 2-s2.0-0035206258 01/22/2002 18 Citations

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. (Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D) Cancer Epidemiol Biomarkers Prev 2001 Jun;10(6):657-61 PMID: 11401916 SCOPUS ID: 2-s2.0-0034905908 06/13/2001 30 Citations

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. (Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK) Ann Oncol 2000 Oct;11(10):1313-22 PMID: 11106122 SCOPUS ID: 2-s2.0-0033758470 12/06/2000 12 Citations

Nitric oxide donor compounds inhibit the toxicity of oxidized low-density lipoprotein to endothelial cells. (Struck AT, Hogg N, Thomas JP, Kalyanaraman B) FEBS Lett 1995 Mar 20;361(2-3):291-4 PMID: 7698340 SCOPUS ID: 2-s2.0-0028956707 03/20/1995 64 Citations

Involvement of preexisting lipid hydroperoxides in Cu(2+)-stimulated oxidation of low-density lipoprotein. (Thomas JP, Kalyanaraman B, Girotti AW) Arch Biochem Biophys 1994 Dec;315(2):244-54 PMID: 7986064 SCOPUS ID: 2-s2.0-0027974212 12/01/1994 97 Citations

Photodynamic therapy. (Kaye AH, Hill JS) J Neurosurg 1994 Apr;80(4):774-5 PMID: 8151365 SCOPUS ID: 2-s2.0-0028207956 04/01/1994

The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. (Whelan HT, Schmidt MH, Segura AD, McAuliffe TL, Bajic DM, Murray KJ, Moulder JE, Strother DR, Thomas JP, Meyer GA) J Neurosurg 1993 Oct;79(4):562-8 PMID: 8410226 SCOPUS ID: 2-s2.0-0027425879 10/01/1993 52 Citations

Hyperexpression of catalase in selenium-deprived murine L1210 cells. (Lin F, Thomas JP, Girotti AW) Arch Biochem Biophys 1993 Aug 15;305(1):176-85 PMID: 8342949 SCOPUS ID: 2-s2.0-0027306178 08/15/1993 20 Citations

Lethal damage to endothelial cells by oxidized low density lipoprotein: role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions. (Thomas JP, Geiger PG, Girotti AW) J Lipid Res 1993 Mar;34(3):479-90 PMID: 8468531 SCOPUS ID: 2-s2.0-0027409382 03/01/1993 139 Citations

Intracellular catalase inhibition does not predispose rat heart to ischemia-reperfusion and hydrogen peroxide-induced injuries. (Konorev EA, Struck AT, Baker JE, Ramanujam S, Thomas JP, Radi R, Kalyanaraman B) Free Radic Res Commun 1993;19(6):397-407 PMID: 8168729 SCOPUS ID: 2-s2.0-0027759676 01/01/1993 12 Citations

Interactions of merocyanine 540 with human brain tumor cells. (Whelan HT, Traul DL, Przybylski C, Segura A, Thomas J, Meyer G, Sieber F) Pediatr Neurol 1992;8(2):117-20 PMID: 1580954 SCOPUS ID: 2-s2.0-0026510921 03/01/1992 6 Citations

Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases. (Geiger PG, Thomas JP, Girotti AW) Arch Biochem Biophys 1991 Aug 01;288(2):671-80 PMID: 1898056 SCOPUS ID: 2-s2.0-0025864673 08/01/1991 52 Citations

Reactivity of phospholipid hydroperoxide glutathione peroxidase with membrane and lipoprotein lipid hydroperoxides. (Maiorino M, Thomas JP, Girotti AW, Ursini F) Free Radic Res Commun 1991;12-13 Pt 1:131-5 PMID: 2071029 SCOPUS ID: 2-s2.0-0026044283 01/01/1991 85 Citations

Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. (Thomas JP, Geiger PG, Maiorino M, Ursini F, Girotti AW) Biochim Biophys Acta 1990 Aug 06;1045(3):252-60 PMID: 2386798 SCOPUS ID: 2-s2.0-0025170978 08/06/1990 163 Citations

Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. (Thomas JP, Maiorino M, Ursini F, Girotti AW) J Biol Chem 1990 Jan 05;265(1):454-61 PMID: 2294113 SCOPUS ID: 2-s2.0-0025060737 01/05/1990 495 Citations

Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. (Thomas JP, Girotti AW) Cancer Res 1989 Apr 01;49(7):1682-6 PMID: 2522345 SCOPUS ID: 2-s2.0-0024516727 04/01/1989 70 Citations

Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Mar;49(3):241-7 PMID: 2525259 SCOPUS ID: 2-s2.0-0024639109 03/01/1989 70 Citations

Reactivity of photochemically-generated lipid hydroperoxides in cell membranes with glutathione peroxidase. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Feb;49(2):153-6 PMID: 2523541 SCOPUS ID: 2-s2.0-0024616037 02/01/1989 17 Citations

Photooxidation of cell membranes in the presence of hematoporphyrin derivative: reactivity of phospholipid and cholesterol hydroperoxides with glutathione peroxidase. (Thomas JP, Girotti AW) Biochim Biophys Acta 1988 Oct 14;962(3):297-307 PMID: 2971397 SCOPUS ID: 2-s2.0-0023755437 10/14/1988 52 Citations

Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism. (Bachowski GJ, Thomas JP, Girotti AW) Lipids 1988 Jun;23(6):580-6 PMID: 3172988 SCOPUS ID: 2-s2.0-0023937941 06/01/1988 52 Citations

Beneficial effects of iloprost in the stunned canine myocardium. (Farber NE, Pieper GM, Thomas JP, Gross GJ) Circ Res 1988 Feb;62(2):204-15 PMID: 2448057 SCOPUS ID: 2-s2.0-0023907033 02/01/1988 77 Citations

Singlet oxygen intermediacy in the photodynamic action of membrane-bound hematoporphyrin derivative. (Thomas JP, Hall RD, Girotti AW) Cancer Lett 1987 Jun;35(3):295-302 PMID: 2954632 SCOPUS ID: 2-s2.0-0023189023 06/01/1987 64 Citations

Photodynamic action of merocyanine 540 on artificial and natural cell membranes: involvement of singlet molecular oxygen. (Kalyanaraman B, Feix JB, Sieber F, Thomas JP, Girotti AW) Proc Natl Acad Sci U S A 1987 May;84(9):2999-3003 PMID: 3033673 PMCID: PMC304788 SCOPUS ID: 2-s2.0-0011230888 05/01/1987 174 Citations

Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothioneins. (Thomas JP, Bachowski GJ, Girotti AW) Biochim Biophys Acta 1986 Dec 10;884(3):448-61 PMID: 3778934 SCOPUS ID: 2-s2.0-0022908892 12/10/1986 226 Citations

Xanthine oxidase-catalyzed crosslinking of cell membrane proteins. (Girotti AW, Thomas JP, Jordan JE) Arch Biochem Biophys 1986 Dec;251(2):639-53 PMID: 3800391 SCOPUS ID: 2-s2.0-0022889439 12/01/1986 48 Citations

Prooxidant and antioxidant effects of ascorbate on photosensitized peroxidation of lipids in erythrocyte membranes. (Girotti AW, Thomas JP, Jordan JE) Photochem Photobiol 1985 Mar;41(3):267-76 PMID: 4011692 SCOPUS ID: 2-s2.0-0022032721 03/01/1985 62 Citations

Lipid photooxidation in erythrocyte ghosts: sensitization of the membranes toward ascorbate- and superoxide-induced peroxidation and lysis. (Girotti AW, Thomas JP, Jordan JE) Arch Biochem Biophys 1985 Jan;236(1):238-51 PMID: 2981506 SCOPUS ID: 2-s2.0-0021907452 01/01/1985 68 Citations

Inhibitory effect of zinc(II) on free radical lipid peroxidation in erythrocyte membranes. (Girotti AW, Thomas JP, Jordan JE) J Free Radic Biol Med 1985;1(5-6):395-401 PMID: 3841804 SCOPUS ID: 2-s2.0-0022332428 01/01/1985 134 Citations

Damaging effects of oxygen radicals on resealed erythrocyte ghosts. (Girotti AW, Thomas JP) J Biol Chem 1984 Feb 10;259(3):1744-52 PMID: 6546380 SCOPUS ID: 2-s2.0-0021265182 02/10/1984 146 Citations

Superoxide and hydrogen peroxide-dependent lipid peroxidation in intact and triton-dispersed erythrocyte membranes. (Girotti AW, Thomas JP) Biochem Biophys Res Commun 1984 Jan 30;118(2):474-80 PMID: 6322749 SCOPUS ID: 2-s2.0-0021366055 01/30/1984 69 Citations

Last update: 10/27/2025

© 2026 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

James P. Thomas PhD, MD

Professor

Publications (75)